Skip to main content

Advertisement

SpringerLink
Log in

Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET)

  • PEDIATRIC NEUROLOGY (HS SINGER, SECTION EDITOR)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Medulloblastoma and central nervous system (CNS) primitive neuroectodermal tumor (PNET) are primary pediatric brain tumors that require multidisciplinary therapies. Although often treated similarly in clinical trials, they are biologically different diseases. Even within medulloblastomas and CNS PNETs, there are molecularly distinct subgroups with differing presentations and prognoses. Overall, prognosis is better for medulloblastomas. Specific treatments for these types of cancer are continuously evolving to maximize survival and minimize long-term sequelae of treatment. Patients should be treated on a clinical trial, if eligible, as they may gain benefit with minimal risk over current standard of care. The amount of residual disease after surgery better correlates with survival for medulloblastomas than for CNS PNETs. Maximal surgical resection of tumor should be done, only if additional permanent, neurologic deficits can be spared. Patients should have a staging work-up to assess the extent of disease. This includes postoperative magnetic resonance imaging (MRI) of the brain, MRI of the entire spine and lumbar cerebrospinal fluid (CSF) sampling for cytological examination, if deemed safe. Radiation therapy to the entire CNS axis is required, with a greater dose (boost) given to the region of the primary site or any bulky residual disease for older children. Adjuvant chemotherapy must be given even if no evidence of disease after radiation therapy exists, as the risk of relapse is substantial after radiation alone. Subsets of younger children with medulloblastoma, arbitrarily defined as those younger than 3 years of age in some studies and 4 or even 5 years in other studies, can be effectively treated with chemotherapy alone. Recent genomic studies have revealed further subtypes of disease than previously recognized. Clinical trials to exploit these biologic differences are required to assess potential efficacy of targeted agents. The treatment of medulloblastoma and CNS PNET can cause significant impairment in neurologic function. Evaluations by physical therapy, occupational therapy, speech therapy and neurocognitive assessments should be obtained, as needed. After therapy is completed, survivors need follow-up of endocrine function, surveillance scans and psychosocial support.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:•• Of major importance

  1. McNeil DE, Coté TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance epidemiology and end results. Med Pediatr Oncol. 2002;39:190–4.

    Article  PubMed  Google Scholar 

  2. Pomeroy SL et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436–42.

    Article  PubMed  CAS  Google Scholar 

  3. •• Taylor MD et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (Berl). 2012;123:465–72. Defines the four molecular subgroups of medulloblastoma and potential biologic markers.

    Article  CAS  Google Scholar 

  4. •• Picard D et al. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012;13:838–48. Identifies subgroups of CNS PNET based on molecular analysis and reports clinical characteristics of each subgroup.

    Article  PubMed  Google Scholar 

  5. CBTRUS (2011) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007. (Central Brain Tumor Registry of the United States, 2011). at <http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf

  6. Albright AL et al. Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery. 1996;38:265–71.

    Article  PubMed  CAS  Google Scholar 

  7. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol. 2004;31:666–75.

    Article  PubMed  Google Scholar 

  8. Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg. 2003;39:60–7.

    Article  PubMed  Google Scholar 

  9. Eberhart CG et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004;63:441–9.

    PubMed  CAS  Google Scholar 

  10. Packer RJ, Macdonald T, Vezina G, Keating R, Santi M. Medulloblastoma and primitive neuroectodermal tumors. Handb Clin Neurol Ed Pj Vinken Gw Bruyn. 2012;105:529–48.

    Article  Google Scholar 

  11. Robertson PL et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children’s Oncology Group. J Neurosurg. 2006;105:444–51.

    PubMed  Google Scholar 

  12. Wells EM et al. Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin. J Neurosurg Pediatr. 2010;5:329–34.

    Article  PubMed  Google Scholar 

  13. Evans AE et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990;72:572–82.

    Article  PubMed  CAS  Google Scholar 

  14. Packer RJ, Sutton LN, D’Angio G, Evans AE, Schut L. Management of children with primitive neuroectodermal tumors of the posterior fossa/medulloblastoma. Pediatr Neurosci. 1985;12:272–82.

    Article  PubMed  Google Scholar 

  15. Zeltzer PM et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:832–45.

    CAS  Google Scholar 

  16. Packer RJ et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202–8.

    Article  PubMed  CAS  Google Scholar 

  17. Fouladi M et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:7152–60.

    Article  Google Scholar 

  18. Lafay-Cousin L et al. Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma. Curr Oncol Tor Ont. 2009;16:21–8.

    Article  CAS  Google Scholar 

  19. Polkinghorn WR et al. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma. Int J Radiat Oncol. 2011;81:e15–20.

    Article  Google Scholar 

  20. Yuh GE et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J Sudbury Mass. 2004;10:386–90.

    Article  Google Scholar 

  21. Garwicz S, Aronson S, Elmqvist D, Landberg T. Postirradiation syndrome and eeg findings in children with acute lymphoblastic leukaemia. Acta Paediatr Scand. 1975;64:399–403.

    Article  PubMed  CAS  Google Scholar 

  22. Littman P et al. The somnolence syndrome in leukemic children following reduced daily dose fractions of cranial radiation. Int J Radiat Oncol Biol Phys. 1984;10:1851–3.

    Article  PubMed  CAS  Google Scholar 

  23. Aguiar D et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol. 2004;66:345–50.

    Article  PubMed  Google Scholar 

  24. Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R. Radiotherapy-induced ear toxicity. Cancer Treat Rev. 2003;29:417–30.

    Article  PubMed  Google Scholar 

  25. Radcliffe J et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol. 1992;32:551–4.

    Article  PubMed  CAS  Google Scholar 

  26. Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol. 2008;65:1419–24.

    Article  PubMed  Google Scholar 

  27. Mulhern RK et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:5511–9.

    Article  Google Scholar 

  28. Oeffinger KC et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–82.

    Article  PubMed  CAS  Google Scholar 

  29. Ullrich NJ et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007;68:932–8.

    Article  PubMed  CAS  Google Scholar 

  30. Geyer JR et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:7621–31.

    Article  Google Scholar 

  31. Rutkowski S et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352:978–86.

    Article  PubMed  CAS  Google Scholar 

  32. Carrie C et al. Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients. Cancer. 1994;74:2352–60.

    Article  PubMed  CAS  Google Scholar 

  33. Prados MD et al. Medulloblastoma in adults. Int J Radiat Oncol. 1995;32:1145–52.

    Article  CAS  Google Scholar 

  34. Chan AW et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery. 2000;47:623–31. discussion 631–632.

    Google Scholar 

  35. Tabori U et al. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer. 2005;103:1874–80.

    Article  PubMed  Google Scholar 

  36. Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer. 2007;110:2035–41.

    Article  PubMed  Google Scholar 

  37. Dhall G et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the ‘Head Start’ I and II protocols. Pediatr Blood Cancer. 2008;50:1169–75.

    Article  PubMed  Google Scholar 

  38. Thorarinsdottir HK et al. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer. 2007;48:278–84.

    Article  PubMed  Google Scholar 

  39. Chi SN et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:4881–7.

    Article  CAS  Google Scholar 

  40. Grill J et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6:573–80.

    Article  PubMed  CAS  Google Scholar 

  41. Rutkowski S et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro-Oncol. 2009;11:201–10.

    Article  PubMed  CAS  Google Scholar 

  42. Leary SES, Zhou T, Holmes E, Geyer JR, Miller DC. Histology predicts a favorable outcome in young children with desmoplastic medulloblastoma: a report from the children’s oncology group. Cancer. 2011;117:3262–7.

    Article  PubMed  Google Scholar 

  43. McEvoy GK, Pharm.D. AHFS drug information®. (American Society of Health-System Pharmacists, Inc.)

  44. Lexi-Comp Online, Pediatric & Neonatal Lexi-Drugs Online. (Lexi-Comp, Inc, 2011). at <http://online.lexi.com/crlsql/servlet/crlonline>.

  45. Green DM et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2009;27:2677–85.

    Article  PubMed  CAS  Google Scholar 

  46. Meistrich ML. Male gonadal toxicity. Pediatr Blood Cancer. 2009;53:261–6.

    Article  PubMed  Google Scholar 

  47. Lawenda BD et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst. 2008;100:773–83.

    Article  PubMed  CAS  Google Scholar 

  48. Bakish J et al. Evaluation of dietetic intervention in children with medulloblastoma or supratentorial primitive neuroectodermal tumors. Cancer. 2003;98:1014–20.

    Article  PubMed  Google Scholar 

  49. Couluris M et al. The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia. J Pediatr Hematol Oncol. 2008;30:791–7.

    Article  PubMed  CAS  Google Scholar 

  50. Bartolo M et al. Early rehabilitation after surgery improves functional outcome in inpatients with brain tumours. J Neurooncol. 2012;107:537–44.

    Article  PubMed  Google Scholar 

  51. Vargo M. Brain tumor rehabilitation. Am J Phys Med Rehabil Assoc Acad Physiatr. 2011;90:S50–62.

    Article  Google Scholar 

  52. Packer RJ et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:3255–61.

    Article  Google Scholar 

  53. Pietilä S et al. Neurological outcome of childhood brain tumor survivors. J Neurooncol. 2012;108:153–61.

    Article  PubMed  Google Scholar 

  54. Lannering B, Marky I, Lundberg A, Olsson E. Long-term sequelae after pediatric brain tumors: their effect on disability and quality of life. Med Pediatr Oncol. 1990;18:304–10.

    Article  PubMed  CAS  Google Scholar 

  55. Packer RJ, Meadows AT, Rorke LB, Goldwein JL, D’Angio G. Long-term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol. 1987;15:241–53.

    Article  PubMed  CAS  Google Scholar 

  56. Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961. Neuro-Oncol. 2013;15:97–103.

    Article  PubMed  CAS  Google Scholar 

  57. Louis DN et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl). 2007;114:97–109.

    Article  Google Scholar 

  58. •• Kool M et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (Berl). 2012;123:473–84. Retrospective analysis correlating molecular subgroups in medulloblastoma with patients characteristics and outcomes.

    Article  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflicts of Interest

Kevin C. De Braganca and Roger J. Packer declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY, 10065, USA

    Kevin C. De Braganca MD

  2. School of Medicine and Health Sciences, George Washington University, Washington, USA

    Roger J. Packer MD

  3. Children’s National Medical Center, Center for Neuroscience Research (CNR), 111 Michigan Avenue, NW, Washington, DC, 20010-2970, USA

    Roger J. Packer MD

Authors
  1. Kevin C. De Braganca MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger J. Packer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin C. De Braganca MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Braganca, K.C., Packer, R.J. Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). Curr Treat Options Neurol 15, 593–606 (2013). https://doi.org/10.1007/s11940-013-0255-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-013-0255-4

Keywords

Search

Navigation